Vericel (VCEL) Competitors

$35.15 -0.25 (-0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$35.14 -0.02 (-0.04%)

As of 05:13 PM Eastern

VCEL vs. QGEN, TGTX, MIRM, SYRE, and RYTM

Should you buy Vericel stock or one of its competitors? MarketBeat compares Vericel with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vericel include Qiagen (QGEN), TG Therapeutics (TGTX), Mirum Pharmaceuticals (MIRM), Spyre Therapeutics (SYRE), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

How does Vericel compare to Qiagen?

Vericel (NASDAQ:VCEL) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Vericel presently has a consensus target price of $55.40, indicating a potential upside of 57.61%. Qiagen has a consensus target price of $44.98, indicating a potential upside of 28.94%. Given Vericel's higher possible upside, equities analysts clearly believe Vericel is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Qiagen has a net margin of 19.16% compared to Vericel's net margin of 7.35%. Qiagen's return on equity of 14.40% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Qiagen	19.16%	14.40%	8.40%

In the previous week, Qiagen had 7 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Qiagen and 4 mentions for Vericel. Vericel's average media sentiment score of 0.67 beat Qiagen's score of 0.03 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has higher revenue and earnings than Vericel. Qiagen is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.50	$16.52M	$0.42	83.69
Qiagen	$2.09B	3.44	$424.88M	$1.91	18.26

70.0% of Qiagen shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vericel has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Summary

Qiagen beats Vericel on 10 of the 16 factors compared between the two stocks.

How does Vericel compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

TG Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Vericel has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Vericel's net margin of 7.35%. TG Therapeutics' return on equity of 88.73% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Vericel	7.35%	6.41%	4.61%

In the previous week, Vericel had 3 more articles in the media than TG Therapeutics. MarketBeat recorded 4 mentions for Vericel and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.84 beat Vericel's score of 0.67 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics presently has a consensus price target of $52.50, indicating a potential upside of 33.79%. Vericel has a consensus price target of $55.40, indicating a potential upside of 57.61%. Given Vericel's higher possible upside, analysts plainly believe Vericel is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

58.6% of TG Therapeutics shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Vericel. TG Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.75	$447.18M	$2.86	13.72
Vericel	$276.26M	6.50	$16.52M	$0.42	83.69

Summary

TG Therapeutics beats Vericel on 13 of the 17 factors compared between the two stocks.

How does Vericel compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Mirum Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Vericel has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Mirum Pharmaceuticals currently has a consensus target price of $137.08, suggesting a potential upside of 36.16%. Vericel has a consensus target price of $55.40, suggesting a potential upside of 57.61%. Given Vericel's higher possible upside, analysts clearly believe Vericel is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vericel has a net margin of 7.35% compared to Mirum Pharmaceuticals' net margin of -140.24%. Vericel's return on equity of 6.41% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Vericel	7.35%	6.41%	4.61%

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Vericel. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 4 mentions for Vericel. Vericel's average media sentiment score of 0.67 beat Mirum Pharmaceuticals' score of 0.64 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.78	-$23.36M	-$13.61	N/A
Vericel	$276.26M	6.50	$16.52M	$0.42	83.69

Summary

Vericel beats Mirum Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Vericel compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Spyre Therapeutics has a beta of 3.12, indicating that its share price is 212% more volatile than the broader market. Comparatively, Vericel has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,251.63	-$155.20M	-$2.08	N/A
Vericel	$276.26M	6.50	$16.52M	$0.42	83.69

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vericel had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 4 mentions for Vericel and 2 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.86 beat Vericel's score of 0.67 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has a net margin of 7.35% compared to Spyre Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.41% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Vericel	7.35%	6.41%	4.61%

Spyre Therapeutics presently has a consensus price target of $90.25, suggesting a potential upside of 21.43%. Vericel has a consensus price target of $55.40, suggesting a potential upside of 57.61%. Given Vericel's higher possible upside, analysts plainly believe Vericel is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Vericel beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Rhythm Pharmaceuticals currently has a consensus price target of $131.81, indicating a potential upside of 46.15%. Vericel has a consensus price target of $55.40, indicating a potential upside of 57.61%. Given Vericel's higher probable upside, analysts clearly believe Vericel is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Rhythm Pharmaceuticals has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market. Comparatively, Vericel has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

In the previous week, Vericel had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 4 mentions for Vericel and 0 mentions for Rhythm Pharmaceuticals. Vericel's average media sentiment score of 0.67 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Vericel is being referred to more favorably in the news media.

Company	Overall Sentiment
Rhythm Pharmaceuticals	Neutral
Vericel	Positive

Vericel has a net margin of 7.35% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Vericel's return on equity of 6.41% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Vericel	7.35%	6.41%	4.61%

Vericel has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	32.57	-$196.54M	-$3.13	N/A
Vericel	$276.26M	6.50	$16.52M	$0.42	83.69

Summary

Vericel beats Rhythm Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCEL vs. The Competition

Export

Metric	Vericel	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.80B	$3.36B	$6.34B	$12.29B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	83.69	19.01	20.92	25.47
Price / Sales	6.50	278.84	521.15	73.36
Price / Cash	62.09	125.35	43.18	55.00
Price / Book	5.04	6.90	9.98	7.00
Net Income	$16.52M	$24.23M	$3.55B	$335.16M
7 Day Performance	6.07%	0.58%	0.40%	-0.29%
1 Month Performance	4.40%	-0.61%	-0.02%	1.18%
1 Year Performance	-14.41%	63.26%	34.94%	34.78%

Vericel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCEL Vericel	3.8447 of 5 stars	$35.15 -0.7%	$55.40 +57.6%	-18.7%	$1.80B	$276.26M	83.69	300
QGEN Qiagen	4.5533 of 5 stars	$32.63 -1.3%	$46.38 +42.1%	-22.0%	$6.81B	$2.09B	17.04	5,654	Analyst Forecast
TGTX TG Therapeutics	4.3371 of 5 stars	$43.14 +0.7%	$52.50 +21.7%	+12.1%	$6.56B	$616.29M	15.08	290
MIRM Mirum Pharmaceuticals	3.0528 of 5 stars	$106.17 -0.9%	$136.42 +28.5%	+113.8%	$6.53B	$521.31M	N/A	140	Analyst Upgrade
SYRE Spyre Therapeutics	2.3025 of 5 stars	$76.43 +1.9%	$89.08 +16.6%	+367.0%	$6.52B	$890K	N/A	73

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCEL) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vericel (VCEL) Competitors

VCEL vs. QGEN, TGTX, MIRM, SYRE, and RYTM

How does Vericel compare to Qiagen?

Summary

How does Vericel compare to TG Therapeutics?

Summary

How does Vericel compare to Mirum Pharmaceuticals?

Summary

How does Vericel compare to Spyre Therapeutics?

Summary

How does Vericel compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vericel (VCEL) Competitors

VCEL vs. QGEN, TGTX, MIRM, SYRE, and RYTM

How does Vericel compare to Qiagen?

Do analysts prefer VCEL or QGEN?

Is VCEL or QGEN more profitable?

Does the media favor VCEL or QGEN?

Which has higher valuation and earnings, VCEL or QGEN?

Do institutionals and insiders believe in VCEL or QGEN?

Which has more risk and volatility, VCEL or QGEN?

Summary

How does Vericel compare to TG Therapeutics?

Which has more volatility & risk, TGTX or VCEL?

Is TGTX or VCEL more profitable?

Does the media refer more to TGTX or VCEL?

Do analysts recommend TGTX or VCEL?

Do insiders and institutionals have more ownership in TGTX or VCEL?

Which has stronger valuation and earnings, TGTX or VCEL?

Summary

How does Vericel compare to Mirum Pharmaceuticals?

Which has more volatility & risk, MIRM or VCEL?

Do analysts prefer MIRM or VCEL?

Is MIRM or VCEL more profitable?

Does the media refer more to MIRM or VCEL?

Which has preferable valuation and earnings, MIRM or VCEL?

Summary

How does Vericel compare to Spyre Therapeutics?

Which has more volatility & risk, SYRE or VCEL?

Which has better earnings & valuation, SYRE or VCEL?

Do institutionals and insiders hold more shares of SYRE or VCEL?

Does the media refer more to SYRE or VCEL?

Is SYRE or VCEL more profitable?

Do analysts rate SYRE or VCEL?

Summary

How does Vericel compare to Rhythm Pharmaceuticals?

Do analysts recommend RYTM or VCEL?

Which has more risk and volatility, RYTM or VCEL?

Does the media prefer RYTM or VCEL?

Is RYTM or VCEL more profitable?

Which has stronger earnings & valuation, RYTM or VCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools